TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05646030

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: TAP-II
Description: The TAP-II device will be compared to lancet capillary sampling and the venipuncture

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: TAP-II
Description: The TAP-II device will be compared to lancet capillary sampling and the venipuncture

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: TAP-II
Description: The TAP-II device will be compared to lancet capillary sampling and the venipuncture

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lancet capillary sampling
Description: The lancet capillary sampling will be compared to TAP device and the venipuncture

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lancet capillary sampling
Description: The lancet capillary sampling will be compared to TAP device and the venipuncture

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lancet capillary sampling
Description: The lancet capillary sampling will be compared to TAP device and the venipuncture

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Venipuncture
Description: The venipuncture will be compared to TAP device and the lancet capillary sampling

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Venipuncture
Description: The venipuncture will be compared to TAP device and the lancet capillary sampling

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Venipuncture
Description: The venipuncture will be compared to TAP device and the lancet capillary sampling
Study: NCT06574568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YKST02
Description: BCMA-CD3 bispecific antibody
Study: NCT05617807

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nanoscopic partial meniscectomy
Description: Patients will have a partial meniscectomy performed using the arthrex nanoscope and it will be compared to partial meniscectomy performed using standard arthroscopic equipment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Partial Meniscectomy
Description: Patients will have partial meniscectomy performed using standard arthroscopic equipment
Study: NCT05853718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide Tablets
Description: Take 25mg TAF daily from week 28-32 of gestation until delivery
Study: NCT05745545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine
Description: One dose was administered by intramuscular injection, 100μg，1.0ml/dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: One dose was administered by intramuscular injection, 0.5ml/vial
Study: NCT05255094

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK102
Description: Administered AK102 by subcutaneous injection every 2 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK102
Description: Administered AK102 by subcutaneous injection every 4 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered placebo by subcutaneous injection every 2 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered placebo by subcutaneous injection every 4 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
Study: NCT06232967

Intervention type: PROCEDURE
Intervention: Primary tumor resection or not
Description: For patients with non-small-cell lung cancer (NSCLC) and dry pleural dissemination, surgical decisions to perform exploratory thoracotomy only or primary tumor resection with wedge resection, segmentectomy, or lobectomy were based on surgeon experience and patient preference.
Study: NCT04878120

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard HCL System
Description: Standard HCL system (USS Virginia)

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard HCL System
Description: Standard HCL system (USS Virginia)

Intervention type: DEVICE
Group type: OTHER
Intervention: HCL System with Smart Bolus Calculator
Description: HCL system (USS Virginia) with smart bolus calculator informed by insulin sensitivity

Intervention type: DEVICE
Group type: OTHER
Intervention: HCL System with Smart Bolus Calculator
Description: HCL system (USS Virginia) with smart bolus calculator informed by insulin sensitivity
Study: NCT05438238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oncomfort
Description: Virtual Reality
Study: NCT05959967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation Exercises
Description: The VRE group will receive exercises aimed at improving gaze stability, postural control, and balance. This includes activities like gaze stabilization exercises, balance training on different surfaces, and walking with head movements.
Study: NCT05337098

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non-Nutritive Sweetener Intake and impact on glucose homeostasis
Description: Provision of either aspartame, sucralose, or control with no non-nutritive sweeteners to a controlled feeding study to determine impacts on glucose homeostasis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Nutritive Sweetener Intake and impact on glucose homeostasis
Description: Provision of either aspartame, sucralose, or control with no non-nutritive sweeteners to a controlled feeding study to determine impacts on glucose homeostasis.
Study: NCT05959967

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Fitness Training
Description: The GFT group will undertake exercises to enhance cardiovascular fitness, strength, and flexibility, such as light aerobic exercises, resistance training, and stretching. The exercise sessions will be 60 minutes in duration, consisting of a warm-up phase, the main exercise phase, and a cool-down phase.
Study: NCT05753436

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Puritans Pride Turmeric curcumin® 500 mg
Description: Turmeric curcumin 500 mg per oral capsule of Puritans Pride company supplement composed of Turmeric (curcuma longa) root 450mg and Turmeric extract (curcuma longa root 50mg ) standardized to contain 95%curcuminoids.It is added because of its possibility to reduce the risk of ASCVD by lowering blood pressure, lipid profile, blood glucose, inflammation, and oxidative stress.
Study: NCT06055504

Intervention type: OTHER
Group type: OTHER
Intervention: Control Strategy
Description: ICDs will be implanted in all patients according to current recommendations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized precision ICD implantation Strategy based in genetic findings and CMR results
Description: Patients allocated to the intervention strategy will receive an ICD according to genetic and CMR results. ICD implantation criteria in patients allocated to the personalised strategy group will be the presence of either a DCM-causing pathogenic or likely pathogenic genetic variants or LGE in CMR. Patients without DCM-associated genetic variants and without LGE on CMR will not receive standard treatment but an ICD will not be implanted on them.
Study: NCT04548284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Periorbital injection of glucocorticoid. Once every 3 weeks, the number of injections was determined according to the condition of the eyes during the follow-up.
Study: NCT06446687

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental implant with sinus lifting.
Description: Surgery will be performed under local infiltration anaesthesia. Flap will be done. For maxillary sinus lifting by using Crestal approach with Membrane Control Technique by Wang (Wang, 2017) will be employed. After reflecting on the flap, Magic Split will be used to confirm bone quality clinically. This will be followed by site preparation using Magic Marking Drill. Bone drilling will then be performed by Magic Drill shorter by 2 mm from the sinus floor. This will be followed by sinus lifting by using Magic Sinus Lifter (MSL). The 3mm space of the apex of the Sinus Lifter instrument enables direct control of the bone-block and consequently the membrane, which is connected to the bone-block. the fixture will be installed in the conventional method. Then cover the fixture with the cover screw. The flap will be sutured. An immediate CBCT will be requested to ensure the implant is in its proper position.
Study: NCT06056843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triage of clinical breast examination positive women using handheld ultrasound by non-radiologists.
Description: Women screened for breast cancer by clinical breast examination (CBE). Those with positive CBE will be triaged by portable ultrasound device by non-radiologists. All recruited women will receive a diagnostic mammography and, if necessary, an ultrasound performed by a radiologist. The radiologist will be blinded to the portable ultrasound device findings. Those with suspected lesions either on mammography or ultrasound will have fine needle aspiration cytology (FNAC) or core biopsy. The women with confirmed diagnosis of breast cancer will be staged and appropriately treated as per the policy of the hospital.
Study: NCT05912829

Intervention type: DEVICE
Intervention: IOL Master 700
Description: Biometry using the IOL Master 700

Intervention type: DEVICE
Intervention: IOL Master 700
Description: Biometry using the IOL Master 700

Intervention type: DEVICE
Intervention: Casia-2
Description: Anterior segment-OCT to evaluate lens tilt

Intervention type: DEVICE
Intervention: Casia-2
Description: Anterior segment-OCT to evaluate lens tilt

Intervention type: DEVICE
Intervention: MS-39
Description: Corneal Topography using the MS-39

Intervention type: DEVICE
Intervention: MS-39
Description: Corneal Topography using the MS-39

Intervention type: DEVICE
Intervention: OSIRIS
Description: Abberometry using the OSIRIS-Abberometer

Intervention type: DEVICE
Intervention: OSIRIS
Description: Abberometry using the OSIRIS-Abberometer

Intervention type: DEVICE
Intervention: Autorefractor
Description: Evaluation of Refraction using an Autorefractor

Intervention type: DEVICE
Intervention: Autorefractor
Description: Evaluation of Refraction using an Autorefractor

Intervention type: DIAGNOSTIC_TEST
Intervention: Subjective Refraction
Description: Refraction performed by experienced staff

Intervention type: DIAGNOSTIC_TEST
Intervention: Subjective Refraction
Description: Refraction performed by experienced staff

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomicroscopy
Description: Slit Lamp Examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomicroscopy
Description: Slit Lamp Examination
Study: NCT04853446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 12 mg
Description: Two identically appearing, opaque capsules will be administered: one capsule containing 12 mg of dexamethasone and one capsule containing placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two identically appearing, opaque capsules will be administered: two capsules containing placebo.
Study: NCT06128421

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Individual nutritional support
Description: Nutritional products and route（oral, parenteral）is possible to reach goals
Study: NCT05709288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBM-H901
Description: Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of an hyper active human factor IX mutant(FIX Padua) transgene in liver. The dose of BBM-H901 is 5x10'12 vg/Kg.
Study: NCT04853446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 24 mg
Description: Two identically appearing, opaque capsules will be administered: two capsules each containing 12mg dexamethasone.
Study: NCT06563999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunvozertinib
Description: 300 mg orally once a day, 28 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: 300 mg orally once a day, 28 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralsetinib
Description: 400 mg orally once a day, 28 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib
Description: 100 mg orally twice daily, 28 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: 600 mg or 400 mg (weight \<50 kg) orally once a day, 28 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: 400 mg orally once a day, 28 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib+Trametinib
Description: Dabrafenib 150 mg orally twice daily, 28 days as one cycle. Trametinib 150 mg orally twice daily, 28 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecirasib
Description: 800 mg daily orally, 28 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: 225 mg daily orally, 28 days as one cycle.
Study: NCT05594797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human BCMA Targeted T Cells Injection
Description: A single dose of predetermined level CAR-positive T cells will be infused.
Study: NCT04770727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT workshop
Description: The CBT based intervention for adolescents will include psychoeducation on food allergy and anxiety and also focus on providing skills, knowledge and support.
Study: NCT06346041

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Virus injection(IDOV-SAFETM)
Description: Administered by intravenous injection as single agent.
Study: NCT04753957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: micronized Progesterone
Description: 200mg micronized progesterone placed vaginally
Study: NCT05923853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FiO2 titration using electronic alert system
Description: In the intervention arm, arterial oxygen saturation (SaO2) and peripheral oxygen saturation (SpO2) will be initially noted. Based on the correlation between the SaO2 and SpO2 the optimal oxygenation range will be determined. E-alerts will then be used to monitor oxygenation for patients in the intervention arm, based on SpO2 values generated by the patient due to the FiO2 given to the patient through the ventilator. Once an e-alert is sent, the respiratory therapist has 45 minutes for adjusting oxygen. Then the e-alert continues to monitor FiO2 and SpO2 values in this manner for every 45 minute period until the ventilator is attached to the patient.
Study: NCT06329258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enstilar
Description: Add on Enstilar

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: 6mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: 6mg QD
Study: NCT04832659

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CEASE
Description: The CEASE intervention is considered the accepted standard of care according to national treatment guidelines. Parents of a child scheduled to be seen at a participating pediatric practice will be provided with a brief intake survey. Office staff and clinicians will be trained how to utilize the intake survey system and how to provide evidence-based cessation assistance to parents who smoke. The brief intake survey will conduct screening to identify household smoking. The CEASE system will provide (1) Automatic documentation of smoking cessation services requested; (2) Automatically generated prescription for nicotine replacement therapy for parents who smoke (unless they opt out of receiving the prescription); (3) Automated enrollment in the state's free tobacco Quitline and the SmokeFreeTXT program, a text message program offered by the National Cancer Institute.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CEASE
Description: The CEASE intervention is considered the accepted standard of care according to national treatment guidelines. Parents of a child scheduled to be seen at a participating pediatric practice will be provided with a brief intake survey. Office staff and clinicians will be trained how to utilize the intake survey system and how to provide evidence-based cessation assistance to parents who smoke. The brief intake survey will conduct screening to identify household smoking. The CEASE system will provide (1) Automatic documentation of smoking cessation services requested; (2) Automatically generated prescription for nicotine replacement therapy for parents who smoke (unless they opt out of receiving the prescription); (3) Automated enrollment in the state's free tobacco Quitline and the SmokeFreeTXT program, a text message program offered by the National Cancer Institute.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CEASE + BIO
Description: Children randomized to the CEASE + BIO group will have leftover blood from an already collected blood sample that was taken for a clinically indicated blood draw analyzed for cotinine. Parents of children in the CEASE +BIO group will receive a report of biomarker results followed by proactive outreach from a BIO counselor. The BIO counselor will explain the laboratory results and refer all parents in the household who smoke to tobacco treatment through the parent's primary care provider and/or the state quitline. The BIO counselor will troubleshoot any barriers to obtaining nicotine replacement therapy that may have been prescribed as part of the CEASE protocol and will promote strict smoke-free and vape-free home and car policies. BIO counselors will conduct a maximum of 6 calls per enrolled smoker.
Study: NCT05525546

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation
Description: One dose of the full-strength conjugate vaccine is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The full-strength conjugate vaccine consists of 25 mcg of each conjugate; Salmonella Enteritidis, Salmonella Typhimurium, and Salmonella Typhi Vi.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation
Description: One dose of the half-strength conjugate vaccine is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The half-strength conjugate vaccine consists of 12.5 mcg of Salmonella Enteritidis, 12.5 mg of Salmonella Typhimurium, and 25 mcg of Salmonella Typhi Vi.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation
Description: One dose of the dilutional half-strength conjugate vaccine is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The dilutional half-strength conjugate vaccine consists of 12.5 mcg of each conjugate; Salmonella Enteritidis, Salmonella Typhimurium, and Salmonella Typhi Vi.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The placebo consists of sterile phosphate-buffered saline (PBS) solution containing polysorbate 80, and 2-phenoxyethanol preservative.
Study: NCT05506969

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rF1V vaccine and CpG 1018® adjuvant
Description: rF1V vaccine and CpG 1018® adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rF1V vaccine and CpG 1018® adjuvant
Description: rF1V vaccine and CpG 1018® adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rF1V vaccine and CpG 1018® adjuvant
Description: rF1V vaccine and CpG 1018® adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rF1V vaccine
Description: rF1V vaccine
Study: NCT06305975

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blunt fascial abdominal entry
Description: Blunt fascial entry technique description: a 5 mm incision is made in the umbilicus. Next, a curved Kelly forceps is used to open the fascia, and, if possible, the peritoneum. The Kelly forceps are then used to expand the opening to a 10 mm diameter. A 5 mm trocar is placed into the fascial hole and used to quickly insufflate the abdomen to 15 mm Hg. Once the abdomen is fully insufflated, a 10 mm trocar is placed using optical guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Veress needle abdominal entry
Description: Veress needle abdominal entry technique description: a 5 mm incision is made in the umbilicus. Next, a Veress needle is used to enter the peritoneal cavity and inflate the abdomen to 15 mm Hg. Once the abdomen is fully insufflated, a 10 mm trocar is placed using optical guidance.
Study: NCT05903157

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group: Delivery of a health literacy flyer
Description: A health literacy flyer was delivered, by e-mail, in the first week of the intervention (the flyer contained its original source - the European Centre for Disease Prevention and Control). Beyond this, there was no further interaction with the group.~All primary and secondary outcome measures were assessed at baseline, one month later (in the middle of the intervention), post-intervention, and follow-up moments (3 and 6 months after the intervention).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group: Weekly group sessions for weight management
Description: The eHealth intervention was designed based on: i) the Health Action Process Approach determinants, ii) the Health Belief Model constructs, and iii) behaviour change techniques (BCT, Taxonomy v1, by Michie et al., 2013) to implement healthy behaviours.~The intervention consists of 8 sessions (90 minutes, once a week). All group intervention sessions, through the Zoom platform, are led by the psychologist responsible for the study. Whatsapp groups were created, to share experiences, knowledge, doubts, fears...~All primary and secondary outcome measures were assessed at baseline, one month later (in the middle of the intervention), post-intervention, and in follow-up moments (3 and 6 months after the intervention).
Study: NCT03735589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-type-1 Polarized Dendritic Cells
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Natural Killer Cell-like CTLs
Description: Given IP
Study: NCT04860440

Intervention type: DEVICE
Intervention: GeneActiv wrist worn accelerometer
Description: Wrist worn device worn for 7 days

Intervention type: DEVICE
Intervention: GeneActiv wrist worn accelerometer
Description: Wrist worn device worn for 7 days
Study: NCT00013247

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Prostate Cancer Screening Education